Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 13/20 | 0.58 |
| ▸ | PGR | P06401 | 5/20 | 0.58 |
| ▸ | ESR1 | P03372 | 4/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3232735 | 0.80 | NR3C1 (0.57) | NR3C1PGRESR1ESR2LMNA | |
| SCHEMBL13458942 | 0.73 | NR3C1 (0.57) | NR3C1PGR | |
| SCHEMBL3234048 | 0.72 | NR3C1 (0.67) | NR3C1PGR | |
| SCHEMBL3229068 | 0.72 | NR3C1 (0.40) | NR3C1PGRPOLBALDH1A1 | |
| SCHEMBL3233100 | 0.72 | NR3C1 (0.58) | NR3C1PGR | |
| SCHEMBL13431431 | 0.71 | NR3C1 (0.55) | NR3C1PGR | |
| SCHEMBL3232655 | 0.69 | NR3C1 (0.55) | NR3C1PGRESR1ESR2POLB | |
| SCHEMBL3235058 | 0.65 | NR3C1 (0.43) | NR3C1PGRLMNAMAPTKDM4E | |
| SCHEMBL3226471 | 0.63 | NR3C1 (0.64) | NR3C1PGR | |
| SCHEMBL29494601 | 0.61 | ESR2 (0.74) | ESR1ESR2MAPTALOX12ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367695-B2 | Condensed tetrahydroquinoline derivative and use thereof for medical purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20100063055-A1 | CONDENSED TETRAHYDROQUINOLINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063055-A1 | CONDENSED TETRAHYDROQUINOLINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | NR3C2, MC2R, NR5A1 | NR3C1 4/4885PGR 11/4885ESR1 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.